175 related articles for article (PubMed ID: 36461687)
1. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
Kalauz A; Tiringer KV; Horváth V; Kapui I
J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Schmidtsdorff S; Schmidt AH
J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
[TBL] [Abstract][Full Text] [Related]
4. Patient In-Use Stability Testing of FDA-Approved Metformin Combination Products for N-Nitrosamine Impurity.
Dharani S; Mohamed EM; Rahman Z; Khan MA
AAPS PharmSciTech; 2024 Jan; 25(1):19. PubMed ID: 38267707
[TBL] [Abstract][Full Text] [Related]
5. International Regulatory Collaboration on the Analysis of Nitrosamines in Metformin-Containing Medicines.
Keire DA; Bream R; Wollein U; Schmaler-Ripcke J; Burchardt A; Conti M; Zmysłowski A; Keizers P; Morin J; Poh J; George M; Wierer M
AAPS J; 2022 Apr; 24(3):56. PubMed ID: 35449372
[TBL] [Abstract][Full Text] [Related]
6. In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products.
Tsuji G; Kurohara T; Shoda T; Yokoo H; Ito T; Masada S; Uchiyama N; Yamamoto E; Demizu Y
Chem Pharm Bull (Tokyo); 2024; 72(2):166-172. PubMed ID: 38296559
[TBL] [Abstract][Full Text] [Related]
7. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
8. Presence of nitrosamine impurities in medicinal products.
Sedlo I; Kolonić T; Tomić S
Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
[TBL] [Abstract][Full Text] [Related]
9. Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography.
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
J Pharm Biomed Anal; 2021 Apr; 197():113960. PubMed ID: 33626447
[TBL] [Abstract][Full Text] [Related]
10. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
11. EDUCATION FROM DERMATOLOGISTS: THE SIMULTANEOUSLY DEVELOPMENT OF 16 KERATINOCYTIC CANCERS AFTER USE OF METFORMIN IN COMBINATION WITH LOSARTAN/ HYDROCHLOROTHIAZIDE, METOPROLOL AND NIFEDIPINE- IMPORTANT LINKS TO DRUG RELATED (PHOTO)-NITROSO-CARCINOGENESIS AND ONCOPHARMACOGENESIS.
Tchernev G; Dimova D
Georgian Med News; 2024 Feb; (347):136-141. PubMed ID: 38609130
[TBL] [Abstract][Full Text] [Related]
12. Development of a new methodology for the determination of N-nitrosamines impurities in ranitidine pharmaceuticals using microextraction and gas chromatography-mass spectrometry.
Giménez-Campillo C; Pastor-Belda M; Campillo N; Hernández-Córdoba M; Viñas P
Talanta; 2021 Feb; 223(Pt 2):121659. PubMed ID: 33298254
[TBL] [Abstract][Full Text] [Related]
13. A Cautionary Tale: Quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin.
Yang J; Marzan TA; Ye W; Sommers CD; Rodriguez JD; Keire DA
AAPS J; 2020 Jul; 22(4):89. PubMed ID: 32613429
[TBL] [Abstract][Full Text] [Related]
14. NDMA Formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product.
Golob N; Peterlin S; Grahek R; Roškar R
J Pharm Sci; 2023 May; 112(5):1277-1286. PubMed ID: 36925105
[TBL] [Abstract][Full Text] [Related]
15. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
16. A survey of industrial N-nitrosamine discharges in Switzerland.
Breider F; Gachet Aquillon C; von Gunten U
J Hazard Mater; 2023 May; 450():131094. PubMed ID: 36867906
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography - tandem mass spectrometry.
Vogel M; Norwig J
J Pharm Biomed Anal; 2022 Sep; 219():114910. PubMed ID: 35779354
[TBL] [Abstract][Full Text] [Related]
18. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
[TBL] [Abstract][Full Text] [Related]
19. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
[TBL] [Abstract][Full Text] [Related]
20. Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products.
Golob N; Grahek R; Ross M; Roškar R
Int J Pharm; 2022 Apr; 618():121687. PubMed ID: 35314277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
